Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Analysis of DNA Damage Now Possible

By LabMedica International staff writers
Posted on 03 Jun 2010
New DNA analysis technology offers a new way to test potential cancer drugs and to determine the effects of environmental toxins.

DNA in living organisms is under constant siege from a variety of damaging agents. More...
Damage to DNA and the ability of cells to repair that damage has wide health implications, from aging and heritable diseases to cancer. Unfortunately, the tools used to study DNA damage are quite limited, but researchers have developed a new tool for rapid DNA damage analysis that has the potential to make an impact on human health.

The researchers, led by Dr. Bevin Engelward, Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) associate professor of biological engineering, and Dr. Sangeeta Bhatia, professor in the Harvard-MIT Division of Health Sciences and Technology and MIT's department of electrical engineering and computer science, have produced a completely revamped version of a 30-year-old lab test known as the comet assay. This new technique combines the versatility and sensitivity of the comet assay for DNA damage analysis with a robust high-capacity platform, which could make DNA damage analysis routine across a variety of applications, ranging from epidemiology to drug screening.

Dr. Engelward, Dr. Bhatia, postdoctoral fellow David Wood and graduate student David Weingeist described the technique in an article that was published in the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) the week of May 3, 2010. The technology could offer a new approach for epidemiologists to detect deadly environmental exposures long before they cause cancer, for clinicians to provide better cancer treatment, and for researchers in the pharmaceutical industry to identify new drugs and screen out hazardous drugs.

The comet assay is based on the idea that during gel electrophoresis, a typically used lab test in which an electric field is applied to DNA placed on a polymer gel, damaged DNA moves farther across the gel than undamaged DNA. The result is a "comet” made of DNA, which looks extraordinarily like its astronomic namesake. The assay is both sensitive and versatile, but it is also time-consuming and tedious. It requires at least one microscope slide for every experimental condition, which means that researchers need to handle dozens of slides just to do a few experimental conditions. Moreover, the readout is manual, meaning researchers have to spend hours staring into a microscope and selecting cells for analysis. The investigator's goal was to harness the strengths of the comet assay while overcoming its limitations in throughput and labor.

Using a micropatterning technique developed by the MIT scientists, the research team imprinted a grid of tiny wells the size of a single cell on a DNA electrophoresis gel. Cells in the array can be individually "addressed,” which allows fully automated readout and replaces the time-consuming manual analysis. They also put their microscopic cell array into a 96-well plate so that many cell types, drugs, or other conditions can be assayed simultaneously. This setup allows dozens of experimental conditions to be tested on just one slide, and it enables slides to be automatically analyzed using custom-designed imaging software.

The team is using knockout cell lines to determine which genetic deficiencies are detectable with their platform and to determine better the molecular mechanisms of DNA repair. They are also optimizing their system for human samples in order to study the DNA damaging effects of the environment. Ultimately, they hope that the CometChip will be commercialized and made available worldwide. This technology was designed not only to enable high throughput screening, but also to be compatible with basic laboratory equipment so that virtually any laboratory can use it.

Related Links:
Massachusetts Institute of Technology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.